AUS
NZ
UK
CA
USA
IND
In the healthcare sector, Swiss pharmaceutical company Roche has secured approval from the U.S. Food and Drug Administration (FDA) for its new treatment, OCREVUS ZUNOVO (ocrelizumab & hyaluronidase-ocsq). This approval allows the use of OCREVUS ZUNOVO for both relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS), providing a new treatment option for individuals with these conditions.
New Treatment for Multiple Sclerosis
Multiple sclerosis (MS) is a chronic and debilitating disease affecting the central nervous system. It occurs when the immune system mistakenly attacks the protective layer surrounding nerve cells, leading to inflammation and damage that can cause a range of physical and neurological symptoms. MS is generally categorized into two forms: relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). Both conditions require ongoing treatment to manage symptoms and slow disease progression.
Roche (OTC:RHHBY)’s newly approved OCREVUS ZUNOVO is notable for being the first and only subcutaneous injection, administered by healthcare professionals twice a year, for both RMS and PPMS. This new injection takes approximately 10 minutes to administer, offering a more efficient option compared to other treatments that often require longer infusion times.
FDA Approval Based on Positive Trial Data
The FDA’s approval of OCREVUS ZUNOVO follows the results of the Phase III OCARINA II trial, which evaluated the safety and efficacy of this subcutaneous injection compared to the intravenous (IV) version of OCREVUS. The trial data showed no clinically significant differences in the blood levels of OCREVUS when administered subcutaneously versus intravenously. Importantly, the safety and efficacy profile of OCREVUS ZUNOVO was found to be consistent with the IV formulation in treating both RMS and PPMS.
One area of note in the trial results was the occurrence of injection reactions. The safety profile of OCREVUS ZUNOVO largely mirrored that of the IV formulation, though injection reactions were more common, particularly with the first administration.
Expanded Options for Multiple Sclerosis Patients
Roche’s chief medical officer, Levi Garraway, highlighted the significance of this approval, noting that OCREVUS ZUNOVO provides both patients and healthcare providers with additional flexibility. With a decade of data supporting the safety and effectiveness of OCREVUS, this new formulation offers an alternative that may better suit the individual needs of patients with multiple sclerosis. The introduction of a subcutaneous option is likely to simplify treatment protocols and improve convenience for many patients.
